SparingVision
Latest round
- Series B
Last raised
- Oct 2022
Total raised
- $57M
Investors
- 7
About SparingVision
Founded in 2016 and based in Paris, France, SparingVision SAS is a biotechnology company that develops SPVN06, a gene therapy-based approach used for treating inherited retinal diseases such as Retinitis Pigmentosa (RP).
Who invested in SparingVision
7 investors across 2 rounds
See all investors in SparingVision
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SparingVision
Who invested in SparingVision?
SparingVision has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SparingVision raised?
SparingVision has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did SparingVision last raise money?
SparingVision's most recent round on record is a Series B, in Oct 2022.
What does SparingVision do?
Founded in 2016 and based in Paris, France, SparingVision SAS is a biotechnology company that develops SPVN06, a gene therapy-based approach used for treating inherited retinal diseases such as Retinitis Pigmentosa (RP).
Where is SparingVision headquartered?
SparingVision is headquartered in Paris, France.
Which VCs invest in companies like SparingVision?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at SparingVision's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like SparingVision? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.